[ad_1]
AstraZeneca has indicated that such a suspension is normal.
The company that is developing the COVID-19 vaccine in collaboration with the University of Oxford is among the favorites in this global race.
“In global randomized trials of the Oxford coronavirus vaccine as part of our standard screening process, we voluntarily stopped vaccination so that safety data could be reviewed by an independent commission,” the spokesperson said.
“This is a routine action that should be taken any time a potentially unexplained illness occurs during one of the investigations and while it is being investigated,” he added.
The company said that occasional illnesses sometimes occur in large investigations, but must be investigated independently.
“We are working to expedite the investigation of this case to minimize any potential impact on the investigation schedule,” the spokesperson said.
It is not yet clear where a clinical trial volunteer is ill and what the nature and extent of their ailments are.
The pause in clinical trials is not uncommon, but it is considered to be the first such COVID-19 vaccine trial in development.
AstraZeneca is among nine companies currently in the final stages of testing vaccines in development.
In the United States, AstraZeneca began registering the necessary 30,000 volunteers at dozens of locations on August 31.
AstraZeneca AZD1222 uses an attenuated common cold adenovirus that has been modified to encode a protein called spine (English spike protein), which allows the new coronavirus to enter cells.
After vaccination, this protein is produced in the human body, which prepares the immune system to attack the coronavirus in the event of a subsequent infection.
[ad_2]
